ACUMEN PHARMACEUTICALS

Acumen Pharmaceuticals to Report Fourth Quarter and Full Year 2021 Financial Results on March 28, 2022

16 Mar 2022 15:15:00 By Nasdaq GlobeNewswire

Acumen Pharmaceuticals to Present at Upcoming Investor Conferences

08 Nov 2021 07:00:01 By Nasdaq GlobeNewswire

Acumen Pharmaceuticals to Present Clinical Trial Design for INTERCEPT-AD, the Phase 1 Placebo-Controlled, Single- and Multiple-Dose Clinical Trial of ACU193, at 2021 Clinical Trials on Alzheimer’s Disease (CTAD) Conference

02 Nov 2021 07:00:01 By Nasdaq GlobeNewswire

Acumen Announces First Patient Dosed in a Phase 1 Clinical Trial of ACU193, a Monoclonal Antibody that Selectively Targets Toxic Aβ Oligomers for the Treatment of Early Alzheimer’s Disease

07 Oct 2021 07:00:01 By Nasdaq GlobeNewswire

Acumen Pharmaceuticals Reports Financial Results for Second Quarter 2021 and Business Highlights

16 Aug 2021 15:05:01 By Nasdaq GlobeNewswire

Acumen Pharmaceuticals Announces Pricing of Upsized Initial Public Offering

30 Jun 2021 21:44:38 By Nasdaq GlobeNewswire